{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T15:06:45Z","timestamp":1782572805099,"version":"3.54.5"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T00:00:00Z","timestamp":1672099200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Auris Nasus Larynx"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.anl.2022.12.013","type":"journal-article","created":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T23:11:05Z","timestamp":1672701065000},"page":"521-533","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of 1.5% levofloxacin otic solution for the treatment of otitis media in a multicenter, randomized, double-blind, parallel-group, placebo-controlled, phase III study"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8668-8341","authenticated-orcid":false,"given":"Masahiro","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiro","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Ikoma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Oka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masako","family":"Terasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7810-5844","authenticated-orcid":false,"given":"Shin","family":"Kariya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruo","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anl.2022.12.013_bib0001","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1128\/AAC.29.1.163","article-title":"Synthesis and antibacterial activities of optically active ofloxacin","volume":"29","author":"Hayakawa","year":"1986","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.anl.2022.12.013_bib0002","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1128\/AAC.32.9.1336","article-title":"In vitro activity of DR-3355, an optically active ofloxacin","volume":"32","author":"Une","year":"1988","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.anl.2022.12.013_bib0003","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/jac\/26.5.659","article-title":"In-vitro and in-vivo activity of DR-3355, an optically active isomer of ofloxacin","volume":"26","author":"Tanaka","year":"1990","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.anl.2022.12.013_bib0004","first-page":"161","article-title":"[The history of the development and changes of quinolone antibacterial agents]","volume":"38","author":"Takahashi","year":"2003","journal-title":"Yakushigaku Zasshi"},{"key":"10.1016\/j.anl.2022.12.013_bib0005","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.1086\/321854","article-title":"Does the dose matter?","volume":"33","author":"Craig","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.anl.2022.12.013_bib0006","first-page":"411","article-title":"Overview of new dosage and administration of levofloxacin, 500 mg once a day","volume":"57","author":"Totsuka","year":"2009","journal-title":"Jpn J Chemother"},{"key":"10.1016\/j.anl.2022.12.013_bib0007","first-page":"201","article-title":"An appropriate selection of antimicrobial agents for intractable otitis media","volume":"55","author":"Fujihara","year":"2007","journal-title":"Jpn J Chemother"},{"key":"10.1016\/j.anl.2022.12.013_bib0008","first-page":"102","article-title":"MIC assay by the micro-dilution (Broth micro-dilution method)","volume":"38","author":"Goto","year":"1990","journal-title":"Chemotherapy"},{"key":"10.1016\/j.anl.2022.12.013_bib0009","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1365-3156.2004.01368.x","article-title":"Topical quinolone vs. antiseptic for treating chronic suppurative otitis media: a randomized controlled trial","volume":"10","author":"Macfadyen","year":"2005","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.anl.2022.12.013_bib0010","first-page":"564","article-title":"[Double-blind comparative study results of ofloxacin otic solution for patients with chronic suppurative otitis media or acute exacerbation of chronic suppurative otitis media.]","volume":"36","author":"Baba","year":"1990","journal-title":"Jibi to Rinsho"},{"key":"10.1016\/j.anl.2022.12.013_bib0011","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1046\/j.1365-2273.1997.00857.x","article-title":"A double blind, prospective trial of topical ciprofloxacin versus normal saline solution in the treatment of otorrhoea","volume":"22","author":"Kasemsuwan","year":"1997","journal-title":"Clin Otolaryngol Allied Sci"},{"key":"10.1016\/j.anl.2022.12.013_bib0012","first-page":"15","article-title":"Antimicrobial therapy in chronic suppurative otitis media","volume":"50","author":"De Miguel Mart\u00ednez","year":"1999","journal-title":"Acta Otorrinolaringol Esp"},{"key":"10.1016\/j.anl.2022.12.013_bib0013","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0001-6519(03)78439-8","article-title":"Use of topical ciprofloxacin in chronic suppurating otitis media","volume":"54","author":"Ramos","year":"2003","journal-title":"Acta Otorrinolaringol Esp"},{"key":"10.1016\/j.anl.2022.12.013_bib0014","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1001\/archotol.1990.01870050057006","article-title":"Topical and oral treatment of chronic otitis media with ciprofloxacin. A preliminary study","volume":"116","author":"Esposito","year":"1990","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.anl.2022.12.013_bib0015","first-page":"106","article-title":"Efficacy of topical ciprofloxacin and tobramycin in combination with dexamethasone in the treatment of chronic suppurative otitis media","volume":"9","author":"Kaygusuz","year":"2002","journal-title":"Kulak Burun Bogaz Ihtis Derg"},{"key":"10.1016\/j.anl.2022.12.013_bib0016","first-page":"521","article-title":"[Multicenter study comparing the efficacy and tolerance of topical ciprofloxacin (0.3%) versus topical gentamicin (0.3%) in the treatment of simple, non-cholesteatomatous chronic otitis media in the suppurative phase.]","volume":"22","author":"Lorente","year":"1995","journal-title":"An Otorrinolaringol Ibero Am"},{"key":"10.1016\/j.anl.2022.12.013_bib0017","doi-asserted-by":"crossref","first-page":"26","DOI":"10.26719\/2001.7.1-2.26","article-title":"Topical ciprofloxacin versus topical gentamicin for chronic otitis media","volume":"7","author":"Nawasreh","year":"2001","journal-title":"East Mediterr Health J"},{"key":"10.1016\/j.anl.2022.12.013_bib0018","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/archotol.1995.01890120070014","article-title":"Treatment of chronic ear disease. Topical ciprofloxacin vs topical gentamicin","volume":"121","author":"Tutkun","year":"1995","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.anl.2022.12.013_bib0019","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3109\/00016489.2013.814154","article-title":"Risk factors for sensorineural hearing loss in chronic otitis media","volume":"133","author":"Luntz","year":"2013","journal-title":"Acta Otolaryngol"},{"key":"10.1016\/j.anl.2022.12.013_bib0020","first-page":"193","article-title":"The sixth nationwide surveillance of clinical isolates from patients with six otolaryngological field infections and antimicrobial susceptibility pattern in the isolated pathogens in Japan","volume":"8","author":"Suzuki","year":"2020","journal-title":"J Jpn Soc Infect Aerosol Otorhinolaryngol"},{"key":"10.1016\/j.anl.2022.12.013_bib0021","series-title":"The interview forms of CRAVIT\u00ae Tablets, fine granules","year":"2019"},{"key":"10.1016\/j.anl.2022.12.013_bib0022","series-title":"The interview forms of CRAVIT\u00ae intravenous drip infusion","year":"2019"},{"key":"10.1016\/j.anl.2022.12.013_bib0023","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/DER.0000000000000160","article-title":"Benzalkonium chloride: a known irritant and novel allergen","volume":"27","author":"Wentworth","year":"2016","journal-title":"Dermatitis"}],"container-title":["Auris Nasus Larynx"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0385814622002425?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0385814622002425?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T19:39:59Z","timestamp":1759952399000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0385814622002425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0385814622002425"],"URL":"https:\/\/doi.org\/10.1016\/j.anl.2022.12.013","relation":{},"ISSN":["0385-8146"],"issn-type":[{"value":"0385-8146","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of 1.5% levofloxacin otic solution for the treatment of otitis media in a multicenter, randomized, double-blind, parallel-group, placebo-controlled, phase III study","name":"articletitle","label":"Article Title"},{"value":"Auris Nasus Larynx","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anl.2022.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Japanese Society of Otorhinolaryngology-Head and Neck Surgery, Inc. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}